Creon Capsule, Delayed Release Pellets
Product Images NDC 0032-1224

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Creon (NDC 0032-1224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Creon Pancrelipase Delayed Release Capsules Spl 01

Creon Pancrelipase Delayed  Release Capsules Spl 01
Creon pancrelipase delayed-release capsules packaging label displaying strengths of lipase 3000 USP units, protease 9500 USP units, and amylase 15000 USP units. The label includes dosage information, storage instructions, warnings, NDC 0032-1203-70, and the AbbVie Inc. labeler name. It features a barcode and placeholder for a 2D barcode on the carton.*
FDA Label Image

Creon Pancrelipase Delayed Release Capsules Spl 02

Creon Pancrelipase Delayed  Release Capsules Spl 02
Creon delayed-release capsules containing pancrelipase with enzyme activities of Lipase 6,000 USP units, Protease 19,000 USP units, and Amylase 30,000 USP units per capsule. The label shows a 100 capsule package by AbbVie Inc., includes warnings, storage instructions, barcode, and NDC 0032-1206-01.*
FDA Label Image

Creon Pancrelipase Delayed Release Capsules Spl 03

Creon Pancrelipase Delayed  Release Capsules Spl 03
Label for Creon delayed-release capsules containing pancrelipase with strengths of Lipase 6,000 USP units, Protease 19,000 USP units, and Amylase 30,000 USP units per capsule. The label includes dosage form and quantity (250 delayed-release capsules) with warnings about seal integrity and capsule handling. Manufactured by AbbVie Inc., it advises storage between 15°C to 25°C and keeping tightly closed and out of reach of children.*
FDA Label Image

Creon Pancrelipase Delayed Release Capsules Spl 04

Creon Pancrelipase Delayed  Release Capsules Spl 04
The packaging label for Creon delayed-release capsules contains pancrelipase as the active ingredient with enzymatic activities of 12,000 USP units lipase, 38,000 USP units protease, and 60,000 USP units amylase per capsule. The label specifies a quantity of 250 capsules, advises to dispense the enclosed medication guide, and includes storage and usage warnings. The product is labeled by AbbVie Inc., North Chicago, IL, and is intended for prescription use only.*
FDA Label Image

Creon Pancrelipase Delayed Release Capsules Spl 05

Creon Pancrelipase Delayed  Release Capsules Spl 05
Creon delayed-release capsules containing pancrelipase with dosages of lipase 12,000 USP Units, protease 38,000 USP Units, and amylase 60,000 USP Units. The label states it is a professional sample, not for resale, and includes storage and handling instructions. Manufactured by AbbVie Inc., North Chicago, IL.*
FDA Label Image

Creon Pancrelipase Delayed Release Capsules Spl 06

Creon Pancrelipase Delayed  Release Capsules Spl 06
Label for Creon delayed-release capsules containing pancrelipase. The label lists dosages for lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units. The package contains 100 delayed-release capsules, labeled by AbbVie Inc. Warnings, dosage recommendations, storage instructions, and a barcode are also visible.*
FDA Label Image

Creon Pancrelipase Delayed Release Capsules Spl 07

Creon Pancrelipase Delayed  Release Capsules Spl 07
Label for Creon delayed-release capsules containing pancrelipase, with strengths of 36,000 USP units of Lipase, 114,000 USP units of Protease, and 180,000 USP units of Amylase per capsule. The label indicates the package contains 100 capsules and is manufactured by AbbVie Inc. It includes dosage and storage warnings, barcode, and prescription-only status.*
FDA Label Image

Creon Pancrelipase Delayed Release Capsules Spl 08

Creon Pancrelipase Delayed  Release Capsules Spl 08
Packaging label for Creon delayed-release capsules containing pancrelipase. The label shows strength of lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units per capsule. It is a 12-capsule package produced by AbbVie Inc. Important storage and usage warnings are visible, along with prescription-only and sample status.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.